Taytulla Kit
Product Images NDC 0023-5862

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Taytulla (NDC 0023-5862). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Following Structural Formula For The Chemical Name Of Ethinyl Estradiol Is [19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17a)-]. The Empirical Formula Of Ethinyl Estradiol Is C20h24o2. (Taytulla 01)

A forest plot titled 'Relevant Studies of Risk of Breast Cancer with Combined Oral Contraceptives.' It compares effect estimates (odds ratios, risk ratios, hazard ratios, and prevalence ratios) from multiple studies evaluating breast cancer risk associated with ever use or current use of combined oral contraceptives versus never use. The horizontal axis shows effect estimates ranging from -1.5 to 2.0 with a vertical line at 1.0 as the null effect. Individual study estimates with confidence intervals are plotted as points with horizontal error bars aligned by study listed on the left.*

FDA Label Image

The Following Structural Formula For The Chemical Name Of Norethindrone Acetate Is [19-norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17a)-]. The Empirical Formula Of Norethindrone Acetate Is C22h28o3. (Taytulla 02)

Chemical structure of the active ingredient norethindrone acetate and ethinyl estradiol shown as a molecular diagram with detailed atom groups and bonds.*

FDA Label Image

Figure 1. Mean Plasma Norethindrone Concentration-time Profiles Following Single- And Multiple-dose Oral Administration Of Norethindrone Acetate/ethinyl Estradiol Tablets To Healthy Female Volunteers Under Fasting Condition (n = 17) (Taytulla 03)

Chemical structure of norethindrone acetate, a component of the drug product Taytulla containing norethindrone acetate and ethinyl estradiol, along with ferrous fumarate. The diagram displays the molecular arrangement including acetate and ethynyl functional groups.*

FDA Label Image

Figure 2. Mean Plasma Ethinyl Estradiol Concentration-time Profiles Following Single- And Multiple-dose Oral Administration Of Norethindrone Acetate/ethinyl Estradiol Tablets To Healthy Female Volunteers Under Fasting Condition (n = 17) (Taytulla 04)

A pharmacokinetic concentration-time graph showing norethindrone plasma concentration (pg/mL) versus time (hours) after dosing. The chart compares norethindrone levels on Day 1 and Day 24, with higher and more prolonged concentrations observed on Day 24 compared to Day 1.*

FDA Label Image

The Following Chart Shows The Chance Of Getting Pregnant For Women Who Use Different Methods Of Birth Control. Each Box On The Chart Contains A List Of Birth Control Methods That Are Similar In Effectiveness. The Most Effective Methods Are At The Top Of The Chart. The Box On The Bottom Of The Chart Shows The Chance Of Getting Pregnant For Women Who Do Not Use Birth Control And Are Trying To Get Pregnant. (Taytulla 05)

A line graph depicting the concentration of ethinyl estradiol (pg/mL) over time (hours) on Day 1 and Day 24. The y-axis shows ethinyl estradiol concentration ranging from 0 to 80 pg/mL, and the x-axis displays time up to 60 hours. Two lines compare concentration decline over time on Day 1 (solid) and Day 24 (dotted).*

FDA Label Image

The Taytulla-pill Pack Has 24 "active" Pink Capsules (with Hormones) To Be Taken For 24 Days, Followed By 4 "reminder" Maroon Capsules (without Hormones) To Be Taken For The Next Four Days. (Taytulla 06)

FDA Label Image

Principal Display Panelndc 0023-5362-30taytulla1 mg/ 20 Mcg28 Day Regimenrx Only (Taytulla 07)

A table chart illustrating pregnancy rates and birth control methods categorized by effectiveness. It shows fewer than 1 pregnancy per 100 women per year for methods like implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, and vaginal ring with hormones. Moderately effective methods like condoms and diaphragm result in 10 to 20 pregnancies per 100 women per year. Less effective methods, including abstinence during fertile days, spermicide, and withdrawal, have more pregnancies, with no birth control resulting in 85 or more pregnancies per 100 women per year.*

FDA Label Image

Taytulla 08

An instructional diagram for Taytulla 1 mg/20 mcg oral contraceptive kit showing a weekly pill organizer. It includes rows for Week 1 to Week 4 and labeled days Sunday through Saturday. Arrows indicate to start on Sunday or Day-1 based on menstrual cycle and to take pills from left to right each week.*

FDA Label Image

Taytulla 09

Taytulla kit packaging label showing the product name and active ingredients: norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, with strength 1 mg/20 mcg. The label also includes the Allergan, Inc. logo and states it provides 28 days of active therapy. The NDC 0023-5862 is partially visible along with a barcode and various instructions on the folded box.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.